Hims & Hers Health, Inc. (HIMS)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3) — the strategy requires fundamentalScore >= 3 before any bullish entry, so no trade plan is built; the technical read is independently bearish (score 1/5: price 17.645 below all moving averages, ADX14 28.04 rising with price, MACD -2.67/-1.87, ~38% below the 20-day high of 28.66), so no setup type qualifies either. Event, liquidity, volatility, overnight-gap and indicator-integrity gates all pass; the block is the fundamental override alone.
Company overview
Hims & Hers Health, Inc. operates a digital health platform connecting users with licensed medical professionals for virtual consultations and ongoing care. The company offers prescription medications, over-the-counter drugs, and wellness products, focusing on general wellness, sexual health, skincare, and hair care. It also distributes products through wholesale partnerships.
Fundamental
weakHims & Hers Health shows deteriorating fundamentals with a net loss and regulatory risks impacting its financial stability.
HIMS reversed from FY2025 GAAP profitability to a nine-month 2026 net loss of $211.4M as gross margin fell to 57% in Q3 and management guided margins to remain below prior periods. Adjusted EBITDA is down 26% year over year, reported operating cash flow of $118.8M depends on about $433M of receivables sold under a new purchase facility, and a $114.8M working-capital deficit sits alongside $607M of obligations due within twelve months. Liquidity of $712M, an undrawn revolver and $1.4B of 0% converts due 2030/2032 keep solvency risk contained, but FTC litigation, an SEC investigation, a DOJ referral and FDA restrictions make the risk profile partly binary. Optically cheap on sales and free cash flow; not cheap on the recurring cash-based picture. Watchlist rather than actionable.
Sentiment
fairSentiment is mixed with no strong catalysts, and ongoing regulatory issues present a two-sided outlook.
Two-sided tape: the 2026-11-09 Q3 print (revenue in line but full-year sales guidance below expectations on climbing costs, announced) is the dominant bearish leg and still being digested, while a genuinely market-rewarded Eli Lilly branded-obesity partnership (2026-11-06, scored +0.6/+0.2 in in-window coverage) supplies the offsetting bullish leg and five states joining the FTC privacy/billing suit keep a confirmed-litigation overhang. Media polarity is determinate but essentially flat (baseline -0.10 → scoring +0.04, off a degraded 5-item scoring sample that missed most of the earnings coverage); the Red-Flag Screen is not clean — no severe flag, but confirmed material litigation plus conflicting actionable catalysts trigger the moderate red-flag cap.
Technical
very weakThe stock is in a bearish trend, trading below all key moving averages with no signs of reversal.
Technical score 1/5 — broken downtrend. Price 17.645 trades below every tracked trend reference: SMA20 24.72, SMA50 27.22, SMA200 26.59, EMA9 20.77, EMA21 23.65, WMA9 19.77, WMA21 22.91, DEMA14 19.00, and the 17.84 daily VWAP (TEMA14 17.66 is the only reference at the price, and it is still overhead). ADX14 at 28.04 and rising from 12.68 on 2026-11-04 marks trend strength on the downside, not a bullish base. RSI14 29.74 and Williams %R -95.92 are oversold, but oversold inside a falling moving-average stack is continuation risk rather than a signal; MACD stays negative at -2.67/-1.87 with a histogram of -0.79 that is barely narrower than the prior session's -0.80, i.e. no confirmed crossover. The tape has lost roughly 38% from the 2026-11-04 high of 28.66 through the 2026-11-09 (-9.2%) and 2026-11-10 (-13.5%) post-earnings sessions and has not reclaimed a single short-term average. Independently of chart quality, the entry is blocked at the gate level: fundamentalScore 2 is below the required floor of 3, so no trade plan is constructed.
You’re looking at 2026-11-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

